| Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Torley Helen | PRESIDENT AND CEO | Jan 19 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Jan 19 05:07 PM | | Torley Helen | PRESIDENT AND CEO | Jan 19 | Sale | 52.41 | 10,000 | 524,140 | 587,177 | Jan 19 05:07 PM | | Torley Helen | PRESIDENT AND CEO | Jan 18 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Jan 19 05:07 PM | | Torley Helen | PRESIDENT AND CEO | Jan 18 | Sale | 51.05 | 10,000 | 510,470 | 587,177 | Jan 19 05:07 PM | | Torley Helen | PRESIDENT AND CEO | Jan 17 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Jan 19 05:07 PM | | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | Jan 17 | Sale | 50.46 | 10,000 | 504,590 | 143,137 | Jan 18 07:07 PM | | Torley Helen | PRESIDENT AND CEO | Jan 17 | Sale | 50.45 | 10,000 | 504,539 | 587,177 | Jan 19 05:07 PM | | Snyder Mark Howard | SVP, GENERAL COUNSEL | Jan 03 | Option Exercise | 0.00 | 7,611 | 0 | 7,611 | Jan 04 06:00 PM | | Torley Helen | PRESIDENT AND CEO | Dec 15 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Dec 15 07:12 PM | | Torley Helen | PRESIDENT AND CEO | Dec 15 | Sale | 57.37 | 10,000 | 573,694 | 587,177 | Dec 15 07:12 PM | | Torley Helen | PRESIDENT AND CEO | Dec 14 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Dec 15 07:12 PM | | Torley Helen | PRESIDENT AND CEO | Dec 14 | Sale | 58.30 | 10,000 | 582,980 | 587,177 | Dec 15 07:12 PM | | Torley Helen | PRESIDENT AND CEO | Dec 13 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Dec 15 07:12 PM | | Torley Helen | PRESIDENT AND CEO | Dec 13 | Sale | 58.66 | 10,000 | 586,627 | 587,177 | Dec 15 07:12 PM | | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | Dec 13 | Sale | 58.67 | 10,000 | 586,675 | 153,137 | Dec 13 06:09 PM | | Posard Matthew L. | Director | Dec 06 | Sale | 56.12 | 10,000 | 561,180 | 105,189 | Dec 06 07:07 PM | | Posard Matthew L. | Director | Dec 05 | Sale | 55.74 | 10,000 | 557,370 | 115,189 | Dec 06 07:07 PM | | Posard Matthew L. | Director | Dec 02 | Sale | 58.80 | 10,000 | 588,000 | 125,189 | Dec 06 07:07 PM | | Torley Helen | PRESIDENT AND CEO | Nov 17 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Nov 17 05:09 PM | | Torley Helen | PRESIDENT AND CEO | Nov 17 | Sale | 52.15 | 10,000 | 521,490 | 587,177 | Nov 17 05:09 PM | | Torley Helen | PRESIDENT AND CEO | Nov 16 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Nov 17 05:09 PM | | Torley Helen | PRESIDENT AND CEO | Nov 16 | Sale | 53.90 | 10,000 | 538,990 | 587,177 | Nov 17 05:09 PM | | Torley Helen | PRESIDENT AND CEO | Nov 15 | Option Exercise | 14.66 | 10,000 | 146,600 | 597,177 | Nov 17 05:09 PM | | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Nov 15 | Sale | 53.81 | 5,000 | 269,053 | 4,045 | Nov 16 07:51 PM | | LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | Nov 15 | Sale | 54.13 | 10,000 | 541,263 | 163,137 | Nov 16 07:25 PM | | Torley Helen | PRESIDENT AND CEO | Nov 15 | Sale | 54.11 | 10,000 | 541,146 | 587,177 | Nov 17 05:09 PM | | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 15 | Option Exercise | 0.00 | 3,386 | 0 | 174,307 | Feb 17 06:04 PM | | LaBrosse Nicole | SVP, Chief Financial Officer | Feb 15 | Option Exercise | 0.00 | 1,255 | 0 | 9,478 | Feb 17 06:03 PM | | Torley Helen | President and CEO | Feb 15 | Option Exercise | 0.00 | 13,092 | 0 | 594,069 | Feb 17 06:02 PM | | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 14 | Option Exercise | 0.00 | 5,771 | 0 | 172,916 | Feb 14 07:29 PM | | LaBrosse Nicole | SVP, Chief Financial Officer | Feb 14 | Option Exercise | 0.00 | 1,256 | 0 | 8,650 | Feb 14 07:28 PM | | Torley Helen | President and CEO | Feb 14 | Option Exercise | 0.00 | 28,729 | 0 | 596,102 | Feb 14 07:27 PM | | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 12 | Option Exercise | 0.00 | 7,883 | 0 | 169,870 | Feb 14 07:29 PM | | LaBrosse Nicole | SVP, Chief Financial Officer | Feb 12 | Option Exercise | 0.00 | 1,389 | 0 | 7,900 | Feb 14 07:28 PM | | Torley Helen | President and CEO | Feb 12 | Option Exercise | 0.00 | 32,795 | 0 | 584,639 | Feb 14 07:27 PM | | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 10 | Option Exercise | 0.00 | 8,133 | 0 | 164,979 | Feb 14 07:29 PM | | LaBrosse Nicole | SVP, Chief Financial Officer | Feb 10 | Option Exercise | 0.00 | 2,503 | 0 | 7,536 | Feb 14 07:28 PM | | Torley Helen | President and CEO | Feb 10 | Option Exercise | 0.00 | 31,282 | 0 | 568,442 | Feb 14 07:27 PM |
|
